Related Experiment Video
Updated: Jul 3, 2026
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
[Practical management of adalimumab]
1Departamento de Dermatología. Hospital Universitario Virgen de la Macarena. Sevilla. España. camachodp@medynet.com
Actas Dermo-Sifiliograficas
|August 19, 2008
Summary
Adalimumab is an effective treatment for moderate-to-severe plaque psoriasis in adults unresponsive to other therapies. This biologic therapy requires careful patient screening and monitoring for optimal outcomes.
Area of Science:
- Immunology
- Dermatology
Context:
- Adalimumab is approved for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
- Previously used off-label for plaque psoriasis under compassionate use programs.
Purpose:
- To outline the appropriate use of Adalimumab for plaque psoriasis.
- To detail patient selection, dosing, and monitoring guidelines.
Summary:
- Adalimumab is indicated for adults with moderate-to-severe plaque psoriasis who have failed or are intolerant to other systemic treatments or phototherapy.
- Pre-treatment screening includes tuberculosis, pregnancy, and Mantoux testing.
- Recommended induction dose is 80 mg at week 0, followed by 40 mg weekly, then 40 mg every two weeks.
- Regular monitoring is advised, with dose adjustments based on response. Discontinuation is recommended before surgery, and live vaccines should be avoided.
Impact:
- Provides a clinical guideline for Adalimumab use in plaque psoriasis.
- Ensures appropriate patient selection and safe administration of this biologic agent.
- Contributes to evidence-based practice in dermatological treatment.
Related Concept Videos
01:24Nephrotic Syndrome III : Nursing Management
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...